A detailed history of Acuta Capital Partners, LLC transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Acuta Capital Partners, LLC holds 190,000 shares of RCKT stock, worth $2.17 Million. This represents 3.55% of its overall portfolio holdings.

Number of Shares
190,000
Previous 250,370 24.11%
Holding current value
$2.17 Million
Previous $5.39 Million 34.9%
% of portfolio
3.55%
Previous 5.8%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$17.6 - $25.88 $1.06 Million - $1.56 Million
-60,370 Reduced 24.11%
190,000 $3.51 Million
Q2 2024

Aug 14, 2024

SELL
$20.66 - $26.72 $1.58 Million - $2.04 Million
-76,417 Reduced 23.38%
250,370 $5.39 Million
Q1 2024

May 15, 2024

SELL
$26.16 - $30.74 $1.03 Million - $1.21 Million
-39,228 Reduced 10.72%
326,787 $8.8 Million
Q4 2023

Feb 14, 2024

BUY
$16.78 - $31.94 $67,371 - $128,239
4,015 Added 1.11%
366,015 $11 Million
Q3 2023

Nov 14, 2023

BUY
$15.07 - $24.05 $840,996 - $1.34 Million
55,806 Added 18.23%
362,000 $7.42 Million
Q2 2023

Aug 14, 2023

BUY
$16.59 - $23.6 $135,938 - $193,378
8,194 Added 2.75%
306,194 $6.08 Million
Q1 2023

May 15, 2023

BUY
$15.79 - $22.6 $600,020 - $858,800
38,000 Added 14.62%
298,000 $5.1 Million
Q4 2022

Feb 14, 2023

BUY
$15.5 - $22.76 $4.03 Million - $5.92 Million
260,000 New
260,000 $5.09 Million
Q1 2021

May 17, 2021

SELL
$43.34 - $65.91 $866,800 - $1.32 Million
-20,000 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$23.3 - $59.57 $466,000 - $1.19 Million
20,000 New
20,000 $1.1 Million
Q2 2018

Aug 15, 2018

SELL
$14.58 - $23.0 $5.1 Million - $8.05 Million
-350,000 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$11.68 - $19.19 $4.09 Million - $6.72 Million
350,000 New
350,000 $6.56 Million

Others Institutions Holding RCKT

About ROCKET PHARMACEUTICALS, INC.


  • Ticker RCKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 75,683,696
  • Market Cap $865M
  • Description
  • Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...
More about RCKT
Track This Portfolio

Track Acuta Capital Partners, LLC Portfolio

Follow Acuta Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acuta Capital Partners, LLC with notifications on news.